29 active shortage notices across 8 countries · 10 anticipated.
Last updated 1 Nov 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Australia | high | 5 | 2 Feb 2026 | 18 Dec 2026 | TGA |
| New Zealand | high | 2 | 2 Jul 2026 | — | Pharmac |
| Germany | high | 1 | 13 Apr 2026 | 17 Jun 2026 | BfArM |
| Italy | medium | 10 | 1 Nov 2025 | 28 Feb 2027 | AIFA |
| Canada | medium | 8 | 14 Jan 2022 | 18 Dec 2026 | HC |
| Ireland | medium | 1 | 28 Aug 2026 | — | HPRA |
| Norway | medium | 1 | 1 Jun 2026 | 21 Aug 2026 | NOMA |
| Greece | medium | 1 | 20 Apr 2026 | — | EOF |
Same-class context from the WHO ATC classification only — not a clinical substitution recommendation, not reviewed by a pharmacist, and not dose-equivalent. Form, strength, route and indication may differ. Confirm any switch with a prescriber.
Yes. As of the latest regulator updates, Temozolomide has 29 active shortage notices across 8 countries (Australia, New Zealand, Germany, Italy, Canada, Ireland and more). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Temozolomide shortages to unexpected increases in demand, manufacturing problems, product discontinuation. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 17 Apr 2026 to 28 Feb 2027, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Mederti lists 6 drugs in the same WHO ATC class as Temozolomide (see above). These are classification context only — not clinically reviewed substitutes. Always confirm any switch with a pharmacist or prescriber and your national guidance.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Dacarbazina · Bendamustina · Bendamustine-Hydrochloride · Busulfano · Cyclophosphamide-Monohydrate · Cyclophosphamid Monohydrat
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.